1 Omega-3 & Aspirin Boost in Periodontal Therapy for Type II Diabetes: A Systematic

- 2 Review
- 3 Emma Walker¹, John Franklin², Jonathan Robinson²
- 4

5 Author Affiliations:

- 6 ¹Clinician, myDentist, Eaglescliffe, UK, Coperate Dental, myDentist, Eaglescliffe,
- 7 Durham, UK TS16 0BU
- ⁸ ²Senior Lecturer in Research Methods, Teesside University, School of Health ans Life
- 9 Sciences, Middlesbrough, UK, TS1 3BA

10

11 **Corresponding Author:**

- 12 Emma Walker Clinician, myDentist, Eaglescliffe, UK, Coperate Dental, myDentist,
- 13 Eaglescliffe, Durham, UK TS16 0BU, Email: walkerel@hotmail.com

14

15 Dr. Jonathan Robinson Teesside University, School of Health and Life Sciences,

16 Middlesbrough, UK, TS1 3BA, Email: J.Robinson@tees.ac.uk

17

18 Acknowledgments, Funding, and Ethics

19 No additional acknowledgments beyond those of the authors have been made, and no 20 funding was provided for this research. No ethical approvals were required for this 21 systematic review.

22

23 Keywords: Periodontal Therapy, Omega-3, Aspirin, Type 2 Diabetes, Systematic Review

24 Abstract

Aim: Omega-3 polyunsaturated fatty acids and aspirin are increasingly explored as adjuncts in periodontal therapy for patients with type II diabetes, owing to their antiinflammatory properties. Despite preliminary evidence suggesting their effectiveness in reducing periodontal inflammation and improving metabolic control, comprehensive evaluations at the clinical level remain limited. This systematic review seeks to critically assess the existing evidence to determine the efficacy of these agents in modifying clinical, biochemical, and metabolic parameters in this high-risk patient group.

32

Methods: A comprehensive search was conducted across electronic databases, including CINAHL, MEDLINE, PubMed, Embase, Dentistry & Oral Sciences Source, and Cochrane Library, to identify relevant studies from inception to January 22, 2024. Included studies were required to be randomised controlled trials and comprise both omega-3 and aspirin as an adjunct to non-surgical treatment. Data extraction was completed independently, and accuracy confirmed by a second reviewer. Data were synthesised using the revised Cochrane risk of bias tool for randomised trials.

40

41 **Results:** A total of 76 records were identified, and three studies met the inclusion criteria.
42 One demonstrated a statistically significant difference in pocket depth, clinical attachment
43 gain and inflammatory markers compared to the control group, and two showed a
44 significant improvement in glycated haemoglobin levels.

45

46

47 **Conclusion**:

48	Omega-3 and aspirin combined have the potential to improve clinical parameters and
49	reduce inflammatory markers in the gingival crevicular fluid. Following non-surgical
50	periodontal treatment, this combination may enhance glycemic control and aid in
51	managing type II diabetes. This systematic review offers insights into the potential
52	effectiveness of omega-3 polyunsaturated fatty acids and aspirin as adjuncts to non-
53	surgical periodontal therapy in patients with type II diabetes and periodontitis. However,
54	current research is limited by small sample sizes and varied study designs. Consequently,
55	there is insufficient evidence to integrate this approach into clinical practice at present.
56	
57	Keywords: Periodontal Therapy, Omega-3, Aspirin, Type 2 Diabetes, Systematic Review
58	
59	
60	
61	
62	
63	
64	
65	
66	

67 **1. INTRODUCTION**

68 Periodontitis is an inflammatory disease that can lead to progressive destruction of the surrounding periodontal tissues, leading to potential tooth loss.¹ Plague formation is 69 70 needed to initiate periodontal inflammation; however, it is not sufficient to induce 71 periodontal destruction by itself.² Destruction is caused by an exaggerated immune-72 inflammatory host response to the microbial challenge,² Periodontal pathogens in plague 73 trigger a pro-inflammatory response involving the recruitment of neutrophils which leads 74 to a local release of reactive free radicals and enzymes which damage the host tissue.³ 75 If there is a constant state of imbalance between the host's immune-inflammatory 76 response and excess bacterial plaque, then disease will occur.³

77

Severe periodontitis is the sixth most prevalent disease worldwide affecting nearly 750 million people.¹ The Adult Dental Health Survey for England, Wales, and Northern Ireland identified 8% of adults have at least one pocket of ≥ 6 mm.⁴ Those experiencing severe periodontitis may experience periodontal inflammation, loss of periodontal attachment, bone loss and tooth mobility which can have a negative impact on daily life.⁵

83

Type II Diabetes Mellitus is a common metabolic disease characterised by a disorder in insulin secretion, insulin resistance or a combination of both resulting in hyperglycaemia.⁶ Prolonged hyperglycaemia causes serious damage to multiple body systems causing disease.⁵ The World Health Organisation estimated there were 422 million adults worldwide with Type II Diabetes Mellitus.⁷ Chee et al.⁸ suggests a bi-directional relationship exists between diabetes and periodontitis. Diabetes does not cause

90 periodontitis but increases the risk for periodontal diseases and in turn may exacerbate
 91 worsening glycaemic control.³

92

93 Glycaemic control is measured by assessing the level of glycated haemoglobin (HbA1c) 94 in the blood, as hyperglycaemia causes glucose to irreversibly bind to the haemoglobin molecule.⁵ HbA1c can be expressed as a percentage which indicates the amount of 95 96 glucose molecules absorbed onto haemoglobin.⁵ Alternatively, HbA1c can be reported in 97 mmols/mol, Non-diabetics have HbA1c levels around 5.5% (37mmol/mol).⁵ Type II 98 Diabetes Mellitus patients with HbA1C levels of <7.0% (53mmol/mol) show good 99 glycaemic control.⁵ Levels above >8-9% (64-75mmol/mol) indicate poor glycaemic 100 control. Complications of diabetes are linked to the level of glycaemic control; it has been 101 shown that the risk of diabetic complication reduces with each 1% reduction in HbA1c.⁵

102

103 Prolonged hyperglycaemia can cause excess glucose in the gingival crevicular fluid 104 (GCF).⁸ Bacteria thrive on sugar and enriched glucose-GCF may alter the bacteria 105 composition within the biofilm which can favour and influence the development of 106 periodontitis.⁹ Diabetics have an impaired neutrophil function, defective chemotaxis and 107 phagocytosis which enables bacterial persistence in the periodontal pocket increasing 108 destruction.³ Often patients have a hyper-responsive monocyte-macrophage phenotype 109 which can increase the production of pro-inflammatory cytokines and mediators.⁸ 110 Elevated levels of pro-inflammatory cytokines accumulating in the GCF is related to 111 glycaemic control.⁸ Mealey et al.⁶ demonstrated Type II Diabetes Mellitus periodontal 112 patients with HbA1c levels >8% had double the amount of interleukin-1b (IL-1b) in the

113	GCF compared to Type II Diabetes Mellitus patients with HbA1c levels <8%. An increase
114	in other inflammatory mediators such as tumour necrosis factor- α (TNF- α) result in
115	increased periodontal inflammation, clinical attachment loss and bone loss. ⁶
116	
117	To our knowledge there have been no systematic reviews which have synthesised the
118	findings of studies investigating the use of omega-3 and aspirin in people with Type II
119	Diabetes Mellitus and periodontal disease. It is therefore the aim of this review to evaluate
120	the effectiveness of omega-3 and aspirin as an adjunct to NSPT in people with Type II
121	Diabetes Mellitus and periodontitis in decreasing clinical, biochemical, and metabolic
122	parameters.
123	
124	2. MATERIAL AND METHODS
125	
126	This Systematic review followed the Preferred Reporting Items of Systematic Reviews
127	and Meta Analyses (PRISMA) guidelines. ¹⁰ The review protocol was registered with
128	PROSPERO, registration number: CRD42022341870 (22 July 2022) at:

129 https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022341870

130

131 2.1 Literature search strategy

Table 1 presents the items using the PICO (participants/patient, interventions,comparators, outcomes) format.

134

135 Table 1: Summary of PICO components

Table 1. PICO objectives.				
Items	Objective			
Patient (P)	periodontitis with diabetes type II.			
Intervention (I)	omega 3, aspirin.			
Comparison (C)	non-surgical periodontal therapy and placebo			
Outcome (O)	reduction in clinical, biochemical, and metabolic parameters, pocket depth (PD), clinical attachment level (CAL), glycated haemoglobin (HbA1c) and inflammatory markers.			

136

137 **2.2 Criteria for Selecting Studies into the Review**

To be included in this review studies were required to meet the following criteria (summarised in table 2): *Population:* Adults (18 years+) with a confirmed diagnosis of both diabetes mellitus type 2 and periodontal disease; *Intervention:* assess the combination of omega-3 and aspirin; *Comparison:* non-surgical periodontal therapy (NSPT) and placebo groups; *Outcome:* assess clinical, biochemical, and metabolic parameters, pocket depth (PD), clinical attachment level (CAL), glycated haemoglobin (HbA1c) and inflammatory markers; *Types of Studies:* be randomised controlled trials.

145

146

	Inclusion criteria	Exclusion criteria
Population	Adults Type II diabetes Periodontal disease	Gingivitis
Intervention	Omega-3 and aspirin	N/A
Comparison	non-surgical periodontal therapy placebo	N/A
Outcome	Pocket depth Clinical attachment level Glycated haemoglobin (HbA1c)	N/A
Types of studies	Randomised controlled trial	Grey literature

148 Table 2: Summary of inclusion and exclusion criteria

149

150 **2.3 Search strategy**

151 An initial search was conducted by two reviewers (EW, JH) for published systematic 152 reviews followed by a comprehensive search of MEDLINE and PubMed to identify 153 relevant terms and citations. An extensive search was then conducted using MEDLINE, 154 PubMed, Embase, Dentistry & Oral Sciences Source, and CINAHL databases in August 155 2022. Box 1 shows an example of a MEDLINE search which was run in each database. 156 Box 1 provides an example of a MEDLINE search that was conducted in each database. 157 Hand searching was completed when a relevant study was found in the text and references of the studies that were identified in the database search. On 22nd January 158 159 2024, all electronic searches were updated.

160

161

163 Box 1: Search terms and Boolean operators used in comprehensive search strategy.

[(periodontitis OR periodontal disease) AND (diabetes mellitus OR diabetic type 2 OR diabetic type II) AND (non-surgical periodontal therapy OR scaling OR debridement) AND (omega-3 poly unsaturated fatty acids OR omega 3 OR docosahexanenoic OR eicosapentaenoic) AND (aspirin OR asa OR acetylsalicylic)]

164

165 **2.4 Selection of studies**

166 One reviewer (EW) transferred the found studies to an Excel spreadsheet whereby all 167 duplicates were detected, deleted, and checked manually for accuracy. This was then 168 imported into Rayvan - a web and mobile app for systematic reviews 169 (https://www.rayyan.ai/,¹¹). Two reviewers (EW and JR) screened all abstracts, and then 170 full-text articles, independently and blindly using Rayyan, based on the PICO framework 171 and inclusion and exclusion criteria (see Table 2). Disagreements between the reviewers, 172 would have been discussed with a third reviewer - no disagreements were found. Cohen's 173 kappa statistic was calculated at each phase of the selection process (title and abstract, 174 and full text) to evaluate agreement between raters.¹²

175

176 **2.5 Data extraction and assessment of risk of bias**

The full-text of the selected articles were read and data extracted by one author (EW). Extracted data included: characteristics of the study and population (i.e., age, sex); definition of diabetes (i.e., type, glycaemic control); definition of periodontitis (i.e., moderate, severe); Intervention (i.e., type, duration) and control group (i.e., placebo

181 contents); and follow up time period and measured outcome parameters. Outcome 182 parameters were pocket depth (PD), clinical attachment level (CAL), glycated 183 haemoglobin (HbA1c), interleukin (IL-1 β) monocyte chemo-attractive protein (MCP) and 184 pentraxin (PTX3). Included studies were required to have one or more test groups and 185 follow up periods. Where data were reported in a box and whisker plot, the Digitizelt software programme¹³ was used to extract data and converted into median interguartile 186 187 range. The included studies were assessed by one reviewer (EW) using a standard table 188 based on the revised Cochrane risk of bias 2.0 tool for randomised trials (RoB 2; ¹⁴).

189

190 **2.6 Data Synthesis**


The synthesis without Meta-Analysis (SWiM) guidelines were used to underpin the synthesis approach.¹⁵ A narrative synthesis approach was used as the synthesis method to summarise the outcome measures. Meta-analysis was not used in this case due to the anticipated heterogeneity.

195

196 **3. RESULTS**

197 **3.1 Study Selection**

The search strategy identified 76 records, of which 11 were duplicates. Sixty-five were screened by reviewing the titles and abstracts and 51 were excluded, and 8 were retrieved for full text review. Three studies met the inclusion criteria (see Table 2). The selection process is summarised in Figure 1. Cohen's kappa statistics measuring interrater agreement for titles and abstracts, and full-text articles were 1 and 1, respectively.



204 Figure 1: PRISMA Flow Chart.

205

207 3.2 Study Characteristics

Included in this review are two blinded randomised controlled trials^{16,17}, and one randomised controlled trial.¹⁸ The population group consisted of males and females who were diabetic and had moderate to severe periodontitis. The included studies involved a total of 157 participants (range 40-75 per study), of which 98 participants were randomly assigned to an intervention group and 59 were assigned to the control group. The typical characteristics of the studies are shown in Table 3.

214

215 Table 3: Summary of papers

Study	Study Design	Country	Sample size Number Male/Female	Population Characteristics	Intervention	Control group	Follow up	Evaluated Parameters
Elwakeel & Hazaa., (2015).	RCT Double- blind Parallel groups	Egypt	40 Control group 10:10. Intervention group 10:10	Mean ± SD age: 40.05 ± 9, (Range 24-58 years) Periodontal Disease: Moderate-severe :≥14 natural teeth, at least 5 teeth with PD≥ mm and CAL≥4 mm Type II Diabetes with HbA1c between 7% and 8%	n = 20, NSPT+omega-3 1000mg 3 times a day+75 mg aspirin once a day, for 6 months	n = 20 NSPT + placebo (Placebo for aspirin: lactose tablet. placebo for×3 PUFAs: coconut oil) once day 6 months	0, 3, 6 months	PD, CAL, GI, PI, GCF levels of IL-1 β and MCP, HbA1c levels
Castro dos Santos et al., (2020).	RCT Double- blind	Brazil	75 Control group 9:16 Intervention grp 1 9:16 Intervention grp 2 12:13	Mean ± SD age: G0: 54.9 ± 9.7 , G1: $55.6 \pm$ 8.3 , G2: 54.4 ± 10.2 Periodontal Disease: Severe- generalised CP: at least 6 sites with PD and CAL≥5 mm and BOP Type II diabetes treated with oral hypoglycaemic and/or insulin with HbA1c ≥ 6.5% to 11%	Group 1: (n = 25) NSPT+Omega-3 900mg +Aspirin 100 mg daily for 2 months after periodontal treatment Group 2: (n = 25) Omega-3 900mg+aspirin 100 mg daily for 2 months before periodontal treatment+ NSPT	n = 25 NSPT + placebo (Not Described) after NSPT 2 months	0, 3, 6 months	PD, CAL, Recession, BOP, PI, IL-1β inflammatory markers, HbA1c levels

				Age range: 30-65 years.				
Rampally et al., (2019).	RCT	India	42 unknown	Periodontal disease: At least 4 teeth with PD ≥5mm CAL ≥ 4mm Type II diabetes taking metformin 500mg per day with HbAlc values ≥6.5%	Group 1: (n = 14) NSPT + aspirin 75mg once daily for 90days Group 2: (n = 14) NSPT + Omega 3 fatty acids 500mg twice daily for 90 days	Group 3: (n = 14) NSPT + placebo (empty gelatine capsule)	0, 3 month	PD, CAL, GI, HbA1c levels, Pentraxin levels

 $[\]begin{array}{lll} \textbf{Key: BOP: Bleeding on probing; CAL: Clinical attachment level; GCF: Gingival crevicular fluid; GI: gingival index; \\ \textbf{HbA1c: glycated haemoglobin; IL-1} interleukin-1} & \textbf{Key: BOP: Bleeding on probing; CAL: Clinical attachment level; GCF: Gingival crevicular fluid; GI: gingival index; \\ \textbf{HbA1c: glycated haemoglobin; IL-1} & \textbf{Interleukin-1} & \textbf{MCP: Monocyte chemo-attractive protein; NSPT: Non-surgical periodontal therapy; PD: probing depth; PI: plaque index; RCT: randomised controlled trial \\ \end{array}$

219

220 3.3 Omega 3 and aspirin

Two studies investigated the effect of omega-3 and aspirin as an adjunct to NSPT.^{16,17} Whereas the third investigated these interventions administered separately.¹⁸ The control group in all three papers were given placebo tablets alongside NSPT for the specified time frames. Only two papers specified the contents of the placebo.^{16,18} The dosage of aspirin ranged between 75 - 100 mg daily and omega-3 ranged between 500 - 3000 mg daily in all. The duration of the administered intervention ranged between 2-6 months.

227

3.4 Non-Surgical Periodontal therapy

Elwakeel et al.¹⁶ performed NSPT with hand scalers and ultrasonic instrumentation in two sessions, over a two-week period. Whereas Castro dos Santos et al.¹⁷ provided this treatment over one session. Both studies reported NSPT was completed by a single periodontist who was blinded to the allocation groups at baseline, and each follow-up appointment. Oral hygiene instruction was given and reinforced at every visit. However, Rampally et al.¹⁸ did not report on how NSPT was performed and whether oral hygiene instruction was given.

236 **3.5 Clinical Parameters**

237 Two studies^{16,18} used a Williams probe whereas the third study¹⁷ used the UNC15 probe 238 to assess the periodontal condition. In each study, PD and CAL were recorded at baseline 239 and at each follow up. Two studies^{16,17} reported that clinical indices were recorded by the 240 same examiner, who remained blinded to allocation and had partaken in calibration 241 exercises (¹⁷: 92%; ¹⁶: k value 0.82). The test group in the study by Elwakeel et al.¹⁶ 242 showed a significant decrease in PD and CAL compared to the control group (p < 0.01). Two papers^{17,18} showed a significant improvement between all groups with regards to 243 244 clinical parameters but failed to establish a statistically significant difference between 245 control and test group (see Table 4). Bleeding on probing (BOP), plague and gingival 246 indices were not collated for this systematic review due to insufficient data to compare for 247 each study.

248

249 **3.6 Biochemical effects**

250 Two studies^{16,17} reported the measurement of multiple inflammatory cytokines in the GCF 251 as IL-1 β and MCP were reported in both studies only this data was collated. IL-1 β decreased over time in both studies. However, only one study¹⁶ showed a statistically 252 253 significant difference compared to the control group (p < 0.01). No significant differences 254 were detected in MCP concentration levels in Castro dos Santos et al.¹⁷, whereas 255 Elwakeel et al.¹⁶ detected a statistically significant difference (p < 0.01) in its MCP levels at 3 and 6 months compared to baseline. Rampally et al.¹⁸ differed due to the absence of 256 257 measuring inflammatory cytokines, instead measuring plasma pentraxin (PTX3) which 258 belongs to the C-reactive protein. The greatest improvement was observed in Test group

- 259 2, followed by Test group 1 and both indicative of a statistically significant difference (p < p
- 260 0.001) compared to the CG (see Table 4).
- 261

262 **3.7 Metabolic Parameters**

263 HbA1c were measured at various time points as shown in table 4 for each study. There

was a marked improvement in HbA1c values across all three studies; however, only one

- study¹⁷ demonstrated a statistically significant difference (p < 0.05) compared to the CG.
- 266

Study	Outcome	TG1 0	TG1 3	TG1 6	TG2 0	TG2 3	ТG2 6	CG 0	CG 3	CG 6
	PD (mm)*	5.7 <u>+</u> 0.8	3.5 <u>+</u> 0.51**	2.8 <u>+</u> 0.52**	_	_	_	5.85 <u>+</u> 0.99	4.55 <u>+</u> 0.83**	3.8 0.7**
Elwakeel	CAL(mm)*	6.05 <u>+</u> 1.76	4.15 <u>+</u> 1.53**	3 <u>+</u> 1.78**	_	_	_	6.6 <u>+</u> 1.19	5.1 <u>+</u> 0.85**	4.2 <u>+</u> 0.52*
& Hazaa. [16].	HbA1c*	7.6 <u>+</u> 0.4	7.43 <u>+</u> 0.37	6.99 <u>+</u> 0.51		_	_	7.59 <u>+</u> 0.33	7.14 <u>+</u> 0.42	7 <u>+</u> 0.4
	IL-1* (pg/mL)	259.8 <u>+</u> 38.8	106.85 <u>+</u> 31.94	65.65 <u>+</u> 13.06**		_	_	268.65 <u>+</u> 34.7	148.7 <u>+</u> 41.59	92.1 <u>-</u> 12.77**
	MCP* (pg/mL)	9.2 <u>+</u> 1.0	6.29 <u>+</u> 0.71	5.47 <u>+</u> 0.83**	_	_	_	9.42 <u>+</u> 1	7.86 <u>+</u> 1.15	6.24 <u>+</u> 0.42*
	PD (mm)*	3.3 <u>+</u> 0.6	2.8 <u>+</u> 0.4	2.9 <u>+</u> 0.4	3.2 <u>+</u> 0.5	3.1 <u>+</u> 0.6	2.9 <u>+</u> 0.4	3.3 <u>+</u> 0.5	2.9 <u>+</u> 0.4	2.9 0.4
Castro dos	CAL (mm)*	3.9 <u>+</u> 0.8	3.5 <u>+</u> 0.8	3.4 <u>+</u> 0.8	3.8 <u>+</u> 0.8	3.8 <u>+</u> 1.0	3.5 <u>+</u> 0.8	3.8 <u>+</u> 0.6	3.5 <u>+</u> 0.7	3.6 0.6
Santos et al.	HbA1c*	8.14	_	7.63**	8.08	_	7.97	8.16	_	8.10
[17].	IL-1º	2.36	1.95	2.04	3.03	2.32	0.82	1.6	3.30	245.29
	MCP∘	311	888.6	342.6	202.5	646.9	303.92	538	514	319.1
	PD*	6.43 <u>+</u> 0.51	4.43 <u>+</u> 0.51	_	6.71 <u>+</u> 0.47	4.71 + 0.47	_	6.43 <u>+</u> 0.51	4.43 <u>+</u> 0.51	_

267 Table 4: Overview of results

Rampally et al.	CAL*	5.43 <u>+</u> 0.51	3.43 <u>+</u> 0.51	_	5.71 <u>+</u> 0.47	3.71 <u>+</u> 0.47	_	5.43 <u>+</u> 0.5	3.43 <u>+</u> 0.51	_
[18].	HbA1c*	8.97 <u>+</u> 1.46	6.98 <u>+</u> 0.88**	—	8.10 <u>+</u> 1.15	7.14 <u>+</u> 1.21**	_	7.54 <u>+</u> 0.82	7.25 <u>+</u> 0.81	_
	Pentraxin*	359.13 <u>+</u> 698.67	101.42 <u>+</u> 72.31**	_	264.5 <u>+</u> 497.5	76.63 <u>+</u> 25.65**	Ι	721.3 <u>+</u> 1934.03	212.44 <u>+</u> 347.01	Ι

Key: CAL, Clinical attachment level, HbA1c, glycated haemoglobin A1c; IL-1, interleukin; MCP, monocyte
 chemoattractant protein. PD, Pocket depth, TG-Test Group. CG-Control group, ** indicates significant difference
 between TG and CG, - indicates data not available in paper.

271

272 **3.8** Risk and quality assessment of bias

Of the three studies included in this systematic review, two scored a low risk of bias and one scored some concerns (see Table 5). Rampally et al.¹⁸ did not report on the randomisation process, allocation concealment, or blinding. Furthermore, the included studies only reported P-values and did not include confidence intervals or effect sizes.

277

278 Table 5: Risk of bias assessment of randomised clinical trials

Risk of bias	Elwakeel & Hazaa. [16]	Castro dos Santos et al. [17]	Rampally et al. [18]
1. Random sequence generation	+	+	?
2. Allocation concealment	+	+	+
3. Blinding or participants and personnel	+	+	?
4. Blinding of outcomes	+	+	+
5. Incomplete outcome data	+	+	+
6. Selective reporting	+	+	+
7. Other sources of bias	+	+	+
8. Bias	Low	Low	Some concerns
9. Reason	N/A	N/A	Some concerns about allocation and randomisation
Key: + = Low risk; ? = Risk not clear			

279 4. DISCUSSION

280 **4.1 Summary of the evidence**

281 This systematic review aimed to investigate the effect of omega-3 and aspirin as adjuncts 282 to non-surgical periodontal therapy (NSPT) in diabetic type II patients with periodontal disease. The review vielded three main findings. Firstly, Elwakeel et al.¹⁶ reported a 283 284 statistically significant difference in periodontal clinical parameters and inflammatory 285 markers (p < 0.01) when NSPT was performed alongside adjunctive omega-3 and aspirin compared to the control group. Secondly, Rampally et al.¹⁸ measured pentraxin levels 286 287 and demonstrated a statistically significant difference compared to a control group (p < p288 0.001). Finally, two studies^{17,18} showed a significant improvement in glycated 289 haemoglobin levels (p < 0.05) compared to the control group.

290

291 Clinical benefits of adjunct usage of omega-3 and aspirin have been observed in previous 292 studies. El-Sharkawy et al.¹⁹ proposed omega-3 and aspirin given for 6 months adjunct 293 to NSPT, documented a greater reduction in PD and CAL in the experimental group 294 compared to a control group. Similarly, Elwakeel et al.¹⁶ observed statistically significant 295 improvements (p < 0.01) in PD and CAL favouring the experimental group after 6 months. 296 In contrast, the remaining studies, despite showing an improvement in these parameters, 297 showed no significant difference between experimental and control groups. An 298 explanation could be due to the dosage of intervention given and the period of time within 299 which it was administered. In the included studies, the dosage of aspirin given daily 300 ranged between 75-100mg, whereas omega-3 varied greatly from 500-3000mg daily. The 301 time frame for the administered interventions in the three studies ranged from 2-6

302 months. This may explain why two of the papers did not yield a significant difference in303 clinical parameters.

304

305 The concentration levels of pro-inflammatory cytokine IL-1 β were measured in two of the 306 included papers.^{16,17} These demonstrated an improvement between all groups for IL-1β; 307 however, only Elwakeel et al.¹⁶ showed a statistically significant reduction (p < 0.01) 308 compared to the control group. This supports the findings by Stadler et al.²⁰ whereby 309 NSPT alone was effective in decreasing GCF cytokine levels in periodontitis after 6 310 months. Alexander et al.²¹ supported the use of omega-3 and aspirin after periodontal 311 flap debridement and demonstrated a significant reduction in levels of IL-1ß after 6 312 months. Only one study measured pentraxin levels (PTX3) which belongs to the family of 313 C-reactive proteins (CRP).¹⁸ There was a significant difference (p < 0.01) in PTX3 levels 314 in both intervention groups compared to the control group. However, the improvement 315 significantly favoured the omega-3 group compared to the aspirin test group when 316 combined with NSPT. CRP serves as an activator for the complement system which 317 assists the innate immune system in the destruction of the periodontium. Telgi et al.²² 318 concluded that NSPT was effective in reducing CRP in GCF; however, this study was 319 conducted on healthy individuals without systemic disease. A more recent systematic 320 review showed dietary omega-3 is associated with lower inflammatory biomarkers in the 321 GCF among diabetics and is a useful therapy for other chronic inflammatory diseases such as cardiovascular disease and rheumatoid arthritis.²³ Therefore, this highlights the 322 323 potential benefit of administering host modulation therapy in patients with risk factors such 324 as systemic diseases like diabetes.

medRxiv preprint doi: https://doi.org/10.1101/2024.10.10.24315256; this version posted October 11, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

325 NSPT is an effective form of removing pathogenic bacteria from the periodontium, which 326 promotes the healing process. However, the healing process in Type II Diabetes Mellitus 327 is more complicated as it is dependent on the level of glycemic control. Research has 328 shown with each 1% reduction in HbA1c levels the risk for Diabetes Mellitus 329 Complications decrease.²⁴ Numerous studies have investigated NSPT on glycaemic 330 control, but the evidence is often conflicting and inconsistent. Some evidence shows 331 positive effects on glycemic control, whereas other researchers have reported NSPT has 332 no effect on glycemic control, besides the improvement on the periodontium.²⁵ Three 333 studies in this review demonstrated an improvement in HbA1c levels across all groups. Two papers^{17,18} showed a statistically significant difference (p < 0.05) favouring the 334 335 experimental group compared to control. A review by Engebretson et al.²⁶ observed a 336 modest reduction in HbA1c levels; however, it concluded that there was limited 337 confidence due to small sample sizes. Other studies have suggested the reduction in 338 HbA1c after NSPT is due to a decrease in the inflammatory burden of pro-inflammatory 339 cytokines such as IL-1 β , IL-6 and TNF-a.²⁷ This finding is consistent with an earlier study by Christgau et al.²⁸ which observed that non-surgical periodontal therapy (NSPT) 340 341 facilitated metabolic control and improved insulin sensitivity by reducing levels of 342 inflammatory cytokines. This raises the issue for further research into the potential benefit 343 of using host modulation therapy as an adjunct to NSPT for diabetics in improving 344 glycaemic control.

345

346

348 **4.2 Quality of the evidence**

349 In this review, two RCTs were considered to have low risk of bias according to the revised 350 Cochrane risk of bias tool for randomised trials (RoB 2). Whereas the third RCT scored 351 some concerns due to selective reporting of how randomisation and blinding were 352 performed. Randomisation methods reported in this review varied and included a simple coin toss and block randomisation. The CONSORT group for reporting clinical trials²⁹, 353 354 however, does not endorse coin tossing as a method of randomisation in an RCT, as it 355 can introduce potential bias. All three RCTs had a control group with a placebo 356 intervention, but only two of these studies^{16,18} gave information on the contents of the 357 placebo used. This could introduce another potential limitation, as the composition of a 358 placebo should be identified in order to determine its influence on the outcome.³⁰ In the three studies reviewed, the NSPT approach varied among the participants in terms of 359 360 frequency, and it remains unclear whether these differences in treatment approach 361 influenced the clinical outcomes observed.

362

The studies included in this review acknowledged certain limitations in their own research. 363 364 These limitations highlighted the need for larger sample sizes and well-designed multi-365 centre studies to provide more robust evidence. One study reported the true benefit of 366 omega-3 and aspirin as an adjunct to NSPT may have surfaced if the intervention had 367 been given for a longer duration. It is evident that the anti-inflammatory effects of this 368 intervention are dose and time dependent. Higher doses of omega-3 and aspirin given for a longer duration have shown to exhibit greater efficacy²³, which is proven by one 369 370 included which reduction study in this review saw a in the measured

371 parameters. However, there are certain drawbacks associated with the use of aspirin and

372 omega-3. Prolonged usage of NSAIDs and high doses of omega-3 have the potential for

373 haemorrhage and gastro-intestinal upset.³¹

374

4.3 Potential limitations in the review process

This review aimed to only investigate the effect of omega-3 and aspirin on diabetic patients. Nonetheless, the comprehensive search strategy uncovered three papers allowing full confidence that all the relevant research was included in this review. English language papers were specified in the inclusion criteria, which could have introduced language bias in this review.

381

382 **4.4 Implications for practice**

383 Current guidelines in the United Kingdom state that NSAIDs and omega-3 given 384 individually as an adjunct to NSPT are not recommended. However, Sanz et al.³² 385 suggests that a combination of omega-3 and low-dose aspirin warrants further 386 assessment in managing periodontitis. This viewpoint aligns with the opinions of other researchers such as Geisinger et al.³³ and Kruse et al.³⁰ who emphasise the need for 387 388 future studies to investigate the use of adjunctive aspirin therapy and omega-3, either 389 individually or in combination, as adjuncts to NSPT in periodontitis patients. These studies 390 highlight the potential value of exploring these interventions further to enhance 391 periodontal treatment outcomes.

393 **4.5 Implications for future research**

394 Despite NSPT being the focus for successful treatment outcomes in periodontitis, adjunct 395 HMT could be indicated in the presence of systemic disease such as diabetes, where 396 NSPT alone may not be enough to decrease clinical, biochemical, and metabolic 397 parameters. Future studies in primary care may be more favourable and should consider 398 or address the methodological limitations of the current published literature. Other 399 recommendations for future research include well-designed RCTs with more uniformity 400 assessing the dosage and duration of the intervention. Evidence reported in clinical trials 401 would be improved by following the CONSORT guidelines.

402

403 **5. CONCLUSION**

404 Omega-3 and aspirin have the potential to decrease clinical parameters and inflammatory 405 markers in the GCF. When administered as an adjunct to NSPT may also improve 406 glycemic control and contribute to the management of type II diabetes. However, it is 407 evident that there were conflicting results as not every paper demonstrated a statistically 408 significant difference in each outcome. As discussed, possible reasons for these results 409 may include the intervention being dose-duration dependent, small sample sizes, and 410 limited evidence currently available. Therefore, due to the uncertainty and limited 411 availability of clinical data at present, there is insufficient evidence to support the use of 412 omega-3 and aspirin as adjuncts to periodontitis in Type II Diabetes Mellitus. Further 413 research addressing the limitations of the current literature is needed.

414

415 **5.1 Implications for Clinical Practice**

The potential benefits of omega-3 and aspirin as adjuncts to NSPT include reductions in periodontal clinical parameters and inflammatory markers, improving periodontal health and possibly glycaemic control. However, inconsistent results and limited evidence mean that their integration into clinical practice should be approached cautiously and requires further validation.

421

422 **5.2 Implications for Research**

Future research should focus on addressing current limitations, including small sample sizes, varying dosages and durations, and inconsistent reporting. Well-designed randomised controlled trials with greater uniformity are necessary to clarify the efficacy of these adjuncts and provide stronger clinical recommendations.

427

428 ACKNOWLEDGMENTS

429 No additional acknowledgments beyond those of the authors have been made.

430

431 CONFLICT OF INTEREST STATEMENT

432 The authors declare no conflicts of interest.

433

434

436 **REFERENCES**

437	1.	Wu C zhou, Yuan Y hang, Liu H hang, Li S sui, Zhang B wen, Chen W, et al.
438		Epidemiologic relationship between periodontitis and type 2 diabetes mellitus. BMC
439		Oral Health. 2020;20:1–15.
440	2.	Donos N, Calciolari E, Brusselaers N, Goldoni M, Bostanci N, Belibasakis GN. The
441		adjunctive use of host modulators in non-surgical periodontal therapy. A systematic
442		review of randomized, placebo-controlled clinical studies. J Clin Periodontol.
443		2020;47:199–238.
444	3.	Eaton KA, Ower P. Practical Periodontics-E-Book. Elsevier Health Sciences; 2022.
445	4.	Digital NHS. Adult Dental Health Survey 2009-Summary report and thematic
446		series. 2011;
447	5.	Casanova L, Hughes FJ, Preshaw PM. Diabetes and periodontal disease: a two-
448		way relationship. Br Dent J. 2014;217(8):433–7.
449	6.	Mealey BL, Ocampo GL. Diabetes mellitus and periodontal disease. Periodontol
450		2000. 2007;44(1):127–53.
451	7.	World Health Organization. Diabetes [Internet]. 2023 [cited 2024 Jan 16]. Available
452		from: https://www.who.int/news-room/fact-sheets/detail/diabetes
453	8.	Chee B, Park B, Bartold MP. Periodontitis and type II diabetes: a two-way
454		relationship. JBI Evid Implement. 2013;11(4):317–29.
455	9.	Gehrig JS, Shin DE, Willmann DE. Foundations of Periodontics for the Dental
456		Hygienist, Enhanced. Jones & Bartlett Learning; 2020.

- 457 10. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al.
- 458 The PRISMA 2020 statement: an updated guideline for reporting systematic 459 reviews. International journal of surgery. 2021;88:105906.
- 460 11. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile
 461 app for systematic reviews. Syst Rev. 2016;5:1–10.
- 462 12. Park CU, Kim HJ. Measurement of inter-rater reliability in systematic review.
 463 Hanyang Medical Reviews. 2015;35(1):44–9.
- 464 13. Bormann I. Digitizelt plot digitizer software. Digitize graphs, charts and math
 465 data[WWW Document] URL http://www digitizeit de/(accessed 117 17). 2017;
- 466 14. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB
 467 2: a revised tool for assessing risk of bias in randomised trials. bmj. 2019;366.
- Campbell M, McKenzie JE, Sowden A, Katikireddi SV, Brennan SE, Ellis S, et al.
 Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline.
 bmj. 2020;368.
- 471 16. Elwakeel NM, Hazaa HH. Effect of omega 3 fatty acids plus low-dose aspirin on
 472 both clinical and biochemical profiles of patients with chronic periodontitis and type
 473 2 diabetes: a randomized double blind placebo-controlled study. J Periodontal Res.
 474 2015;50(6):721–9.
- 475 17. Castro dos Santos NC, Andere NMRB, Araujo CF, de Marco AC, Kantarci A, Van
 476 Dyke TE, et al. Omega-3 PUFA and aspirin as adjuncts to periodontal debridement
 477 in patients with periodontitis and type 2 diabetes mellitus: randomized clinical trial.
 478 J Periodontol. 2020;91(10):1318–27.

18. Rampally P, Koduganti RR, Ganapathi SN, Panthula VR, Surya PJ. Comparison of
effectiveness of low-dose aspirin versus omega-3 fatty acids as adjuvants to
nonsurgical periodontal therapy in Type II diabetic patients with chronic
periodontitis. J Indian Soc Periodontol. 2019;23(3):249.

- EI-Sharkawy H, Aboelsaad N, Eliwa M, Darweesh M, Alshahat M, Kantarci A, et al.
 Adjunctive treatment of chronic periodontitis with daily dietary supplementation with
 omega-3 fatty acids and low-dose aspirin. J Periodontol. 2010;81(11):1635–43.
- 486 20. Stadler AF, Angst PDM, Arce RM, Gomes SC, Oppermann R V, Susin C. Gingival
 487 crevicular fluid levels of cytokines/chemokines in chronic periodontitis: a meta488 analysis. J Clin Periodontol. 2016;43(9):727–45.
- Alexander DCC, Martin JC, King PJ, Powell JR, Caves J, Cohen ME. Interleukin-1
 beta, prostaglandin E2, and immunoglobulin G subclasses in gingival crevicular
- 491 fluid in patients undergoing periodontal therapy. J Periodontol. 1996;67(8):755–62.
- Telgi RL, Tandon V, Tangade PS, Tirth A, Kumar S, Yadav V. Efficacy of
 nonsurgical periodontal therapy on glycaemic control in type II diabetic patients: a
 randomized controlled clinical trial. J Periodontal Implant Sci. 2013;43(4):177–82.
- 495 23. Balta MG, Papathanasiou E, Blix IJ, Van Dyke TE. Host modulation and treatment
 496 of periodontal disease. J Dent Res. 2021;100(8):798–809.
- 497 24. Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, et al. 498 Association of glycaemia with macrovascular and microvascular complications of 499 2 diabetes (UKPDS 35): prospective observational study. Bmj. type 500 2000;321(7258):405–12.

- 501 25. Teshome A, Yitayeh A. The effect of periodontal therapy on glycemic control and 502 fasting plasma glucose level in type 2 diabetic patients: systematic review and 503 meta-analysis. BMC Oral Health. 2017;17(1):1–11.
- Engebretson S, Kocher T. Evidence that periodontal treatment improves diabetes
 outcomes: a systematic review and meta-analysis. J Clin Periodontol.
 2013;40:S153–63.
- Jones JA, Miller DR, Wehler CJ, Rich SE, Krall-Kaye EA, McCoy LC, et al. Does
 periodontal care improve glycemic control? The department of veterans affairs
 dental diabetes study. J Clin Periodontol. 2007;34(1):46–52.
- 510 28. Christgau M, Palitzsch K, Schmalz G, Kreiner U, Frenzel S. Healing response to 511 non-surgical periodontal therapy in patients with diabetes mellitus: clinical, 512 microbiological, and immunologic results. J Clin Periodontol. 1998;25(2):112–24.
- 513 29. Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines
 514 for reporting parallel group randomised trials. BMJ. 2010 Mar 23;340(mar23
 515 1):c332–c332.
- 516 30. Kruse AB, Kowalski CD, Leuthold S, Vach K, Ratka-Krüger P, Woelber JP. What is
 517 the impact of the adjunctive use of omega-3 fatty acids in the treatment of
 518 periodontitis? A systematic review and meta-analysis. Lipids Health Dis.
 519 2020;19:1–16.
- 520 31. Elkhouli AM. The efficacy of host response modulation therapy (omega-3 plus low-521 dose aspirin) as an adjunctive treatment of chronic periodontitis (clinical and 522 biochemical study). J Periodontal Res. 2011;46(2):261–8.

523	32.	Sanz M, Herrera D, Kebschull M, Chapple I, Jepsen S, Berglundh T, et al.
524		Treatment of stage I–III periodontitis—The EFP S3 level clinical practice guideline.
525		J Clin Periodontol. 2020;47:4–60.
526	33.	Geisinger ML, Holmes CM, Vassilopoulos PJ, Geurs NC, Reddy MS. Adjunctive
527		treatment of chronic periodontitis with systemic low-dose aspirin therapy. Clin Adv
528		Periodontics. 2012;2(3):195–9.